Clinical Trials Browser

Unknown × INDUSTRY × orelabrutinib × Clear all

NCT05234684 2024-02-07

BELIEVE-01

Phase 3 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT05978739 2023-10-25

Evaluating Different Doses of Orelabrutinib in MCL

Phase 2 Unknown

Lymphoma, Mantle-Cell

NCT04014205 2023-04-18

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Phase 1/2 Unknown

Part 1：r/r B-cell Malignancies